Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feladilimab (GSK3359609) Monotherapy and Combination in Advanced Solid Tumors
NCT02723955Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 9
01
Overview
Phase 1, open-label trial of feladilimab in bladder cancer, Cervical Cancer (CC), colorectal cancer (CRC) and 6 more, sponsored by GSK. Primary endpoints: Adverse Events up to 367 weeks, Dose Limiting Toxicity up to 28 days and 2 more. Started Jun 2016; status: completed.
02
Drugs
feladilimab
03
Conditions
bladder cancerCervical Cancer (CC)colorectal cancer (CRC)esophageal cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02723955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723955.